Featured Story | By Annalee Armstrong Bristol Myers Squibb is presenting data this weekend that shows its targeted heart drug mavacamten helped reduce the risk of needing septal reduction therapy. read more |
| |
|---|
|
More From ACC 2022 By Kevin Dunleavy At the American College of Cardiology conference Monday in Washington, D.C., Bayer presented the latest findings on its diabetic kidney cancer drug Kerendia, discovered by pooling two trials. The company believes the findings will help guide it to more uses for Kerendia. read more By Conor Hale Using Huawei devices equipped with the same light-based sensors found on Apple Watches, Fitbits and more, researchers found a free app could track a person’s pulse and issue an alert when it falls out of sync. read more By Conor Hale Medtronic continues to build up clinical data for its kidney nerve ablation procedure for treating stubborn high blood pressure. A randomized clinical study has shown significant and sustained reductions after three years. read more By Kevin Dunleavy At the American College of Cardiology in Washington, D.C., Lexicon highlighted results from a trial of sotagliflozin in Type 2 diabetes and kidney disease patients that showed the drug not only reduced heart failure by 26% but also reduced the risk of stroke and heart attack. read more By Max Bayer Ionis Pharmaceutical, in need of a win after a high profile pipeline flop last week, has found that its AstraZeneca-partnered cholesterol med lowered levels of the troublesome substance in patients during a mid-stage trial. read more By Andrea Park More than a decade after first earning the FDA’s sign-off for its Zio ECG patch, iRhythm is still churning out data to prove beyond a shadow of a doubt the heart monitor’s ability to spot atrial fibrillation and other arrhythmias as early as possible. read more By Conor Hale Undergoing a medical procedure is always a stressful prospect for a patient—so much so that, at times, their anxieties are simply considered unavoidable. But Philips is looking to make the entire experience just a little less scary. read more | 